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Europe has an envied reputation for excellent 
epidemiologic monitoring of virus diseases, even when 
there were few antiviral drugs with which to treat 
them. More are now being developed and, because 
they are, and are likely to continue to be, highly specific 
for individual viruses (or, at best, groups of viruses), 
there will be a continuing need for rapid and equally 
specific diagnostic tests to identitj. acute infections with 
them. In this context, rapid really does mean exactly 
that. The answer has to be available in hours if an 
antiviral is to have any chance of being effective-even 
overnight will be too long in most cases, particularly 
where life-threatening disease is involved. 
There have been, and are, useful and effective 
vaccines to prevent infections with some viruses, 
although others have proved intractable. The good 
vaccines included those against smallpox, polio and 
measles, and there is a reasonable hope that the latter 
two will join smallpox in oblivion early in the next 
Millenium. Respiratory viruses, like influenza and 
respiratory syncytial virus, offer more difficult chal- 
lenges, yet to be solved fully [1,2], although the new 
antineuraminidase drugs for influenza show promise 
Underpinning the evidence of a need for an anti- 
viral drug, and confirming its effectiveness in use, must 
be rapid and accurate diagnosis of virus infections. 
Many such diseases, particularly in the early stages, 
present as ‘flu-like’, with more characteristic features 
developing later, if at  all. Hence, rapid diagnosis must 
be adequately specific and capable of distinguishing, if 
necessary, between closely related strains. Moreover, 
where vaccines are type-specific, and many are, only 
type-specific diagnosis can point to the need for a 
vaccine and monitor a vaccine’s effectiveness. It, too, 
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must be rapid to confirm an epidemic and to counter- 
act common assumptions that all cases in an epidemic 
are due to the same virus-respiratory viruses fre- 
quently overlap in both symptoms and signs (41. 
Two recent trends are threatening this availability 
of specific diagnosis, and are already having an effect in 
those countries in the world where there is a good 
diagnostic service. They are, first, the increasing and 
relentless pressure on the funds for health care, and, 
second, the increasing availability of commercially 
produced diagnostic kits. I wish to examine each in 
turn, though they are clearly linked, noting that the 
advent of the latter may be thought to be a help to the 
former. 
PRESSURE ON HEALTHCARE FUNDS 
Treatments for diseases of all kinds tend to become 
more expensive as new ones are developed and new 
diseases identified. Many conditions, inevitably fatal in 
the past, can now be cured, or alleviated. Cancers, 
leukemias and organ failures can be managed with 
cytotoxic drugs and/or transplants. New drugs to 
combat old conditions, drug-resistant bacteria and 
fungi, and organ rejection, are being evaluated and 
adopted into regular use. Few of them are cheap. 
Not surprisingly, healthcare budgets everywhere 
are feeling great pressure, and both clinicians and 
administrators are being forced to decide priorities [5], 
including where diagnostic virology can fit into them. 
Many virus infections do not have specific drugs to cure 
them quickly, and most (in otherwise healthy indi- 
viduals) are self-limiting anyway. Under these circum- 
stances, there is a temptation to restrict diagnostic 
virology to what is simple and straightforward (e.g. the 
less expensive serology) and to reduce the number of 
specialist viroiogy laboratories in each country to one 
or two centralized facilities. The main function of these 
central reference laboratories would be to serve the 
epidemiologic needs of the country. Routine diag- 
nostic needs could then be met by multidisciplinary 
machine-based assays on serum samples. 
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COMMERCIAL KITS 
Before the development of monoclonal antibodies, 
commercially produced diagnostic kits or reagents were 
impractical-good polyclonal antisera were in very 
short supply, being produced, with a huge investment 
in time and effort, in small quantities by individual 
laboratories for their own use [6]. There was never a 
surplus, at any price, for any commercial enterprise to 
contemplate marketing kits based on them. Moreover, 
the realistic cost of such sera would have made any such 
kit unacceptably expensive for routine use. 
Monoclonal antibodies completely changed the 
ground rules. Reliable antisera in almost unlimited 
quantities could now be produced and these could be 
used to standardize reagents for diagnostic use, as well 
as providing positive control sera. Kits followed rapidly, 
particularly for hepatitis B and HIV/AIDS, where there 
was, and is, a huge demand for screening blood and 
blood products for evidence of past infection before use 
[7]. The technology developed for these two viruses 
was soon adapted to others, and a variety of reagents, 
kits and systems for routine diagnosis have flooded onto 
the marke tso  much so that laboratories have found 
that, provided they used enough of the material or kits, 
they often did not have to buy the otherwise expensive 
machine on which to run them; it would be readily 
available on loan. Further, similar enzyme-linked assays 
became available for other branches of laboratory 
medicine, particularly biochemistry, and one machine 
might, in theory, fulfill everyone’s needs. So far, this 
form of rationalization has been slow to catch on but, 
as money becomes ever tighter, the pressure towards it 
will rise. Such assays are based on measuring levels in 
serum, and, in virologic terms, this means measuring 
antibody levels. These rise far too slowly to be useful 
in rapid diagnosis, but many still believe that ‘viral 
titers’ provide the essence of virologic diagnosis. Virus 
titers may be helpful in some cases, but only in retro- 
spect; they have no place in deciding antiviral treat- 
ment, except in continuing infections such as AIDS and 
hepatitis. 
More recently, nucleic acid amplification tech- 
niques (polymerase chain reaction (PCR), ligase chain 
reaction (LCR), nucleic acid sequence-based ampli- 
fication (NASBA), etc.) have offered another new 
approach to diagnosis [8] .  Their extreme sensitivity, 
combined with not having to recover live virus, has 
meant that, again in theory, very small quantities (down 
to a few genome copies) could be identified using 
primers made in unlimited quantities. Inevitably, diag- 
nostic kits have appeared, and their use and value are 
being explored [9]. These kits are not cheap and need 
high-class laboratory techniques to be reliable, but they 
are being hailed as a possible way to avoid the need for 
cell culture. Whether they can be rapid and cheap 
enough for routine use remains to be seen but, since 
they require known primer sequences, they cannot 
work with novel viruses. Cell culture is one of the 
traditional diagnostic tools, but one that is expensive in 
skilled staff time, reagents and space and impossible to 
standardize. 
Commercial kits also promise another bonus-that 
of standardization. If all laboratories use the same, or 
similar, equally and centrally validated kits, their results 
should be comparable [lo]. The resultant data could 
then, in theory at least, give a more reliable continent- 
wide or worldwide picture of the epidemiology of 
individual viruses. Moreover, with the responsibility for 
developing and validating tests taken out of health 
service laboratories, it could be argued that the need 
for specialist virologists would then be reduced. They 
would only be needed in the few specialist laboratories; 
routine diagnosis could be supervised by microbiologists. 
NEW VIRAL ACTIVITIES 
Overall, this paints a gloomy picture for those who have 
chosen to specialize in virology. Do they have a future? 
Of course they do, because this concept of trivial 
infections being simply and easily diagnosed by sero- 
logic and nucleic acid amplification tests run on large 
machines using commercial kits is far too simplistic. 
Nonetheless, the reasons why this is so must be spelt 
out clearly, and quickly, before the virologists have 
become discouraged and disappeared. 
The main reason is that viruses and their activities 
are continually changing. Such manifestations will in- 
clude the appearance of new viruses, recognition of 
new activities by ‘old’ viruses or by new variants of ‘old’ 
viruses. 
NEW VIRUSES 
‘New’ viruses are still emerging, though most are not 
truly new-they have just not been encountered in 
humans before. Their new role in human disease comes 
from humans altering their environment and habits: 
holidaymakers go further afield than before, there is still 
a drift towards the cities, wars and deprivation are still 
common, diets change, and so on. Table 1 lists the 
viruses that have been recognized as new infections 
since 1970, and the list is not yet complete. When such 
novel infections surface, they may do so anywhere, at 
any time. How severe and widespread they will be 
cannot be predicted. It is essential that they are 
identified and confirmed as soon as possible, and their 
progress monitored. 
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Table 1 New or re-emergent viruses since 1970 
Bornaviruses 
Bunyaviruses 
Hantaviruses: Hantaan, Sin Nombre, etc. 
Gastroenteropathy viruses 
Caliciviruses (including Norwalk and small round structured 
viruses), rotavirus, adenoviruses 40 and 41, astrovirus, small 
round viruses, fecal coronaviruses (?), picobirnaviruses (?) 
Hemorrhagic viruses 
Filoviruses: Ebola and Marburg (re-emergent) 
Arenaviruses: Guanarito, Junin, Sabia, etc. 
Hepatitis viruses 
Hepatitis C and GB variants, delta agent (hepatitis D), 
hepatitis E, more? 
Human herpesviruses 
HHVh, HHV7, HHV8 
Human retroviruses 
HIV-1, HIV-2, HTLV-1, HTLV-2 
Orthomyxoviruses 
Influenza A: H l N l  (re-emergent), H3N2 (drift strains), 
H5N1 and H9N2 (novel) 
Papovaviruses 
77 genotypes 
NEW ACTIVITIES BY ‘OLD’ VIRUSES 
Two possible scenarios are possible under this heading. 
The first is importation of known viruses into new 
areas, and recent cases of yellow fever imported into 
Germany in 1999, and originally thought to be due to 
Ebola virus, provide a good example. Global warming 
may bring insects, and the viruses they transmit, to areas 
previously free from them [l 11. 
Second, with increasing numbers of immuno- 
compromised patients, either because their natural 
immunity is deficient or absent, or because they are 
on immunosuppressive drugs (for malignancies or 
following transplants), otherwise relatively harmless 
viruses can become seriously life-threatening. Cytome- 
galovirus (CMV) is normally a silent infection, but 
reactivation in transplant patients or those with AIDS 
can be very serious and is the most widely known 
example [12], although it is not the only one. When 
CMV recurs, high and apparently adequate doses of 
appropriate antiviral drugs often fail to eliminate CMV 
activity, and exactly why this happens is unclear [13]. 
Such patients are increasingly managed in district 
hospitals, but specialist virology has to be close at hand 
for this to be done properly. With more anti-CMV 
drugs becoming available to help to manage this 
problem, the patients must also be monitored for the 
appearance of resistant strains of the virus [14]. Just as 
importantly, progress in reducing virus activity must be 
assessed regularly. Failure to achieve undetectable levels 
can be due to developing resistance, but this may 
not be the only reason. Assumption is not enough; 
the real reason must be found if the problem is to be 
solved. 
However, CMV is not the only virus to infect 
immunocompromised patients; others may be associ- 
ated with very similar, and usually indistinguishable, 
clinical pictures [15]. A drug effective against CMV 
would be totally unsuitable for treating these other 
viruses, confirming the need for correct identification 
of both the true virus cause and its part in causing the 
clinical picture. 
NEW VARIANTS OF ’OLD VIRUSES 
Influenza A is the best example of this problem. The 
R N A  genomes of both influenza A and B are unstable, 
leading to antigenic ‘drift’, in which their surface 
antigens alter a little each year, possibly as a result of 
immune pressure, so that over several years mutants 
gradually outflank existing herd immunity [ 161. In 
addition, influenza A can undergo major antigenic 
changes through acquiring new segments of R N A  by 
genetic reassortment with animal strains [ 161. These 
major ‘shifts’ occur at infrequent and unpredictable 
intervals, but are important because the new strains 
have changed their antigenic outer clothes to such an 
extent that no existing immunity in the community 
is effective and a worldwide pandemic may follow. 
Should this occur again (the last time was in 1968), 
there will be an urgent need for a new vaccine to 
protect the vulnerable. If the new strain is as pathogenic 
as Spanish flu was in 1918, the entire community will 
be at  serious risk. The recent isolation of H5N1 [17] 
and H9N2 (J.S.M. Peiris, personal communication) 
strains of influenza A viruses in Hong Kong confirm 
that ‘shift’ changes occur and these dangers are not just 
theoretical. The formulation and production of any 
form of vaccine will depend on isolating and charac- 
terizing the new strain as quickly as possible. 
New serotypes of other ‘old’ viruses are still being 
identified. These include adenoviruses, often in 
patients with AIDS [18]. Vigilance may reveal other 
examples. 
Even without these new developments, we have 
not solved all the existing virologic problems. There 
remain annual epidemics of respiratory syncytial virus 
(RSV) affecting thousands of babies each year, many of 
them requiring hospital admission [ 191. Routine 
diagnosis defines and reminds LIS of the size of the 
problem-it does not go away because the reports dry 
up. An effective vaccine has been sought for a long time 
but a satisfactory one has yet to be found [l]. 
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CONCLUSIONS 
AU these viral activities should be monitored if measures 
to control them can be logically devised. Some are 
predictable, e.g. the annual RSV epidemic [20], though 
serologic diagnosis has been found to be far too 
unreliable [21], but the possibility of new viruses means 
that some catch-all techniques must be available. These 
are methods (cell culture and electron microscopy) 
which do not depend on pre-existing reagents, which 
will not be available for any novel viruses. Both 
methods, however, are under threat as being unaccept- 
ably expensive, but at present there are no  practical 
alternatives. Neither method is suited to general micro- 
biology laboratories because they require specialist skills 
which, to remain acceptably reliable, must be kept in 
regular daily use. 
These factors encapsulate the virologic dilemma 
for health services-how many virus laboratories does 
a country need? For many European countries, a single 
centralized one might be thought enough, particularly 
in a geographically small country, but will not be 
adequate for two reasons. First, virus diagnosis works 
best over short (within city) distances, so that clinicians 
and senior laboratory staff can work in partnership, 
each knowing the other as individuals. Absence of 
contact leads to reliance on ‘virus titers’ alone. 
Secondly, the virologic staffing structure must be large 
enough to give the trainee virologists reasonable career 
prospects. These arguments would point towards a 
need for a virologist in every district general hospital. 
As a virologist, I would personally welcome this 
conclusion, but this is (probably!) being unrealistic. 
There has to be a balance between too many and too 
few. There have to be as many laboratories as are 
necessary to ensure adequate and sufiiciently broad 
monitoring, both epidemiologically and of individual 
patients, with properly trained and experienced staff in 
daily practice with the necessary catch-all techniques. 
At present, in the UK, too many senior vacancies are 
left unfilled-for example, during the last 10 years, four 
Consultant posts in Glasgow, two in Newcastle, one in 
Edinburgh, one in Leeds, one in Leicester. If this trend 
is not reversed, specialist virologists will become extinct 
through attrition, and because trainees will find their 
career prospects much greater in other specialities. The 
value of virology services directed by fully trained and 
in-practice speciahsts to transplant units, pediatricians, 
AIDS clinics, intensive therapy units (ITUs), epidemio- 
logists, developers of vaccines and antiviral drugs (and 
those that evaluate them in trials) and commercial 
companies must be recognized, and their survival 
planned. Concerns about new viral activities develop- 
ing in the community, and not being recognized until 
too late, were expressed as long ago as May 1989 at a 
meeting in Washington, DC on ‘Emerging viruses: the 
evolution of viruses and viral diseases’, sponsored by 
NIH in cooperation with The Rockefeller University. 
These well-justified anxieties were later published as a 
book [22], in which Donald Henderson, architect of 
the W H O  Smallpox Eradication Campaign, proposed 
a network of nationally based surveillance laboratories 
[23] .  This is, one would have thought, only common 
sense, but no  network can survive without staff, trained 
and in regular practice, to do the basic tasks of looking 
for new viruses or changes in the pattern of ‘virus-like’ 
diseases. In other words, they must be in post, and kept 
in practice by being given routine tasks to do. Now, 10 
years later, the situation has got gradually worse and 
there still seems to be far too little awareness of the 
danger of losing the necessary breadth of techniques 
necessary for adequate surveillance, staffed by fully 
trained and experienced card-carrying virologists 
deploying their traditional slulls. 
This review has focused on the laboratory tech- 
niques that a community needs to have available to 
monitor virus activities. They are, however, all but use- 
less without suitably trained staff in adequate numbers 
to use them. A later review will discuss how they can 
be provided and maintained within hard-pressed health 
care budgets. 
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